Exclusive partnership introduces globally benchmarked stem cell processing platform aimed at improving stem cell recovery, quality, and long-term therapeutic potential
New facility will open by October 2026 and house 500 process development specialists
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
The new institute will strengthen oncology infrastructure in central India with advanced radiation therapy, multidisciplinary expertise, and comprehensive cancer care services
Both nations deepen cooperation in health innovation, AI-driven healthcare, biomedical research, data sharing, and life sciences to accelerate next-generation healthcare solutions
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments
Award highlights Hyderabad-based innovation hub’s role in advancing healthcare technology, clinical intelligence, and global operational excellence
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
